Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Billings, L. K., Hsia, S., Bays, H., Tidemann-Miller, B., O’Hagan, J., Tham, L. S., Butler, A., Kazda, C., Mather, K. J., & Coskun, T. (2025). Lancet (London, England), S0140-6736(25)02155-5. Advance online publication.

2025 Nov 6

DOI: 10.1016/S0140-6736(25)02155-5

No folders found. Please create and select folder.

Documents

Folder Title Following special characters are not supported: \ / ? % * : | " < >

Privacy

Public All Members My Connections Only Me

Cancel Create

PIIS0140673625021555.pdf 685 KB PDF - Click to view

Options

• Copy Download Link